Estimating the optimal individualized treatment rule from a cost‐effectiveness perspective-Reference-Cited by-同舟云学术

Estimating the optimal individualized treatment rule from a cost‐effectiveness perspective

Published:2020-12-09 Issue: Volume: Page:
ISSN:0006-341X
Container-title:Biometrics
language:en
Short-container-title:Biometrics

Author:

Xu Yizhe¹^ORCID,Greene Tom H.¹²³,Bress Adam P.¹,Sauer Brian C.¹³⁴,Bellows Brandon K.⁵,Zhang Yue¹²³,Weintraub William S.⁶,Moran Andrew E.⁵,Shen Jincheng¹²³

Affiliation:

1. Department of Population Health Sciences University of Utah Salt Lake City Utah

2. Department of Internal Medicine University of Utah Salt Lake City Utah

3. Department of Family and Preventive Medicine University of Utah Salt Lake City Utah

4. Salt Lake City Veterans Affairs Medical Center Salt Lake City Utah

5. Department of Medicine Columbia University Medical Center New York New York

6. MedStar Health Research Institute Washington DC

Funder

Center for Clinical and Translational Science, University of Utah

National Heart, Lung, and Blood Institute

Publisher

Wiley

Subject

Applied Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/biom.13406

Reference48 articles.

1. Using Microsimulation Models to Inform U.S. Health Policy Making

2. ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

3. Estimating medical costs with censored data

4. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating Individualized Treatment Regimes to Optimize Incremental Cost-Effectiveness Ratio;Statistics in Biosciences;2024-07-04

2. Incorporating participants’ welfare into sequential multiple assignment randomized trials;Biometrics;2024-01-29

3. Thompson Sampling Algorithm for Personalized Treatment Recommendations in Healthcare;2023 International Conference on Artificial Intelligence for Innovations in Healthcare Industries (ICAIIHI);2023-12-29

4. Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial;Expert Review of Pharmacoeconomics & Outcomes Research;2023-12

5. Identifying optimally cost-effective dynamic treatment regimes with a Q-learning approach;Journal of the Royal Statistical Society Series C: Applied Statistics;2023-03-07